Democratizing Cellular Immunotherapy The Paradigm Shift to In Vivo CAR-T Cell Engineering

Abstract

Objective: Chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment of hematologic malignancies but remain inaccessible to the vast majority of the global population due to exorbitant costs (>$400,000) and complex ex vivo manufacturing logistics. This paper evaluates the efficacy and economic viability of in vivo CAR-T cell generation as a scalable solution for global health equity.

Methods: A comprehensive review of preclinical and clinical data published between 2024 and 2025 was conducted, focusing on two primary in vivo delivery platforms: viral vectors (VivoVec) and targeted lipid nanoparticles (tLNPs). Additionally, the cost-effectiveness of India’s indigenous ex vivo therapy, NexCAR19, was analyzed as a benchmark for frugal innovation.

Results: Recent trials indicate that in vivo engineering can achieve therapeutic efficacy comparable to traditional methods without lymphodepleting chemotherapy. The INVICTA-1 trial (viral vector) and preclinical data from Capstan Therapeutics (tLNPs) demonstrate successful B-cell depletion and immune reset. Economic modeling suggests in vivo approaches could reduce the cost of goods sold (COGS) by over 90% compared to current US standards, surpassing the affordability milestones set by NexCAR19.

Conclusion: In vivo CAR-T therapy represents a transformative leap in oncology, potentially converting a bespoke luxury treatment into a globally distributable biologic. Harmonized regulatory frameworks and cold-chain innovations are now the primary barriers to widespread implementation.

Keywords: In vivo CAR-T, global oncology, health equity, immunotherapy, viral vectors, lipid nanoparticles, NexCAR19.

Introduction

The disparity in cancer care between high-income countries (HICs) and low- and middle-income countries (LMICs) is expanding alongside the complexity of novel therapeutics. While the advent of Chimeric Antigen Receptor (CAR) T-cell therapy has provided curative outcomes for patients with refractory leukemias and lymphomas, its delivery model is fundamentally unscalable. The current standard of care—autologous ex vivo CAR-T—requires extracting a patient’s T-cells (leukapheresis), shipping them to a centralized manufacturing hub for genetic reprogramming, and returning them for reinfusion. This "vein-to-vein" cycle typically costs between $373,000 and $475,000 per dose in the United States, excluding the substantial costs of hospitalization and management of toxicities like cytokine release syndrome (CRS) (Association of Community Cancer Centers [ACCC], 2025).

For 90% of the world’s population, this logistical and financial burden renders CAR-T therapy inaccessible. The infrastructure required—sterile Good Manufacturing Practice (GMP) facilities, reliable ultracold chains, and specialized personnel—is scarce in resource-limited settings (Hwang et al., 2025). To address this, the field of oncology is pivoting toward two distinct solutions: "frugal innovation" to lower the cost of ex vivo manufacturing, and a radical technological shift to in vivo engineering, where the patient’s body serves as the bioreactor.

This paper critically analyzes the most effective and affordable advancements in CAR-T therapy as of late 2025. It examines the success of India's NexCAR19 as a proof-of-concept for cost reduction and argues that in vivo delivery systems—specifically surface-engineered viral vectors and targeted messenger RNA (mRNA) lipid nanoparticles (LNPs)—constitute the ultimate solution for global distribution.